Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Accumulated Expenses (2020 - 2025)

Bolt Biotherapeutics' Accumulated Expenses history spans 6 years, with the latest figure at $3.8 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 17.98% year-over-year to $3.8 million; the TTM value through Sep 2025 reached $3.8 million, up 17.98%, while the annual FY2024 figure was $4.2 million, 31.01% down from the prior year.
  • Accumulated Expenses for Q3 2025 was $3.8 million at Bolt Biotherapeutics, up from $3.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $15.1 million in Q4 2022 and bottomed at $3.3 million in Q3 2024.
  • The 5-year median for Accumulated Expenses is $5.7 million (2022), against an average of $6.5 million.
  • The largest annual shift saw Accumulated Expenses soared 287.12% in 2021 before it plummeted 59.76% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $12.4 million in 2021, then rose by 22.25% to $15.1 million in 2022, then tumbled by 59.76% to $6.1 million in 2023, then crashed by 31.01% to $4.2 million in 2024, then decreased by 8.66% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Accumulated Expenses are $3.8 million (Q3 2025), $3.3 million (Q2 2025), and $6.5 million (Q1 2025).